Molecular Insights into Marine Sponge-Derived Bromotyrosine Alkaloids: Emerging Therapeutic Perspectives against Triple-Negative Breast Cancer
DOI:
https://doi.org/10.64229/fx40k580Keywords:
Bromotyrosine, Marine alkaloids, Natural, Pharmacognosy, Progesterone, Triple-negative breast cancerAbstract
Triple-negative breast cancer (TNBC) ranks as one of the most deadly and difficult-to-treat types of carcinomas of the breast, distinguished by the absence of oestrogen & progesterone receptors, as well as HER2. Therefore, therapies are constrained and present hormonal and targeted therapies are ineffective. Results of chemotherapy are subpar over the long term, and this underlines the acute necessity of innovative treatments. Recent research in marine natural products such as the bromotyrosine alkaloids found in marine sponges, however, has sparked interest in oncology, as they are characterized by their extraordinary chemical diversity and multitargeted biological activity. Their uniqueness as brominated scaffolds due to the presence of apoptotic properties allows both apoptotic control and cell cycle and epigenetic regulation. In this review, there is a need to initiate a consistent pharmacognostic endeavor to investigate bromotyrosine alkaloids through organized extraction techniques, elucidations of chemical structures and thorough biological characterization. Recent developments such as analytical discoveries, bioassay-guided isolation, and some new formulation approaches are outlined, along with preclinical efficacy and safety information. The findings suggest that TNBC has considerable therapeutic potential, with the potential of clinical translation of the findings and suggests that interdisciplinary research plays important role in providing direction to the development of these compounds. The results support the radical value of bromotyrosine alkaloids and promote the practical development to the next generation of oncological drugs.
References
[1]Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: A review. The Cancer Journal, 2021, 27(1), 8-16. DOI: 10.1097/PPO.0000000000000500
[2]Miglietta F. Breast cancer biological characterization-evaluation of the prognostic and/or predictive role of clinical, pathological and molecular biomarkers to dissect breast cancer heterogeneity: Focus on estrogen-low breast cancer. 2024.
[3]Hilliard C B. Ancestral genomics: African American health in the age of precision medicine. Harvard University Press, 2024.
[4]Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M, et al. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Molecular Biomedicine, 2025, 6(1), 2. DOI: 10.1186/s43556-024-00239-2
[5]Religioni U, Barrios-Rodríguez R, Requena P, Borowska M, Ostrowski J. Enhancing therapy adherence: Impact on clinical outcomes, healthcare costs, and patient quality of life. Medicina, 2025, 61(1), 153. DOI: 10.3390/medicina61010153
[6]Yu J, Wang X, Du P, Shi H. The therapeutic potential and application of marine alkaloids in treating breast cancer. Frontiers in Marine Science, 2024, 11, 1440928. DOI: 10.3389/fmars.2024.1440928
[7]Morais SR, KC, Jeyabalan S, Wong LS, Sekar M, Chidambaram K, et al. Anticancer potential of Spirastrella pachyspira (marine sponge) against SK-BR-3 human breast cancer cell line and in silico analysis of its bioactive molecule sphingosine. Frontiers in Marine Science, 2022, 9, 950880. DOI: 10.3389/fmars.2022.950880
[8]Kim JA, Choi SS, Lim JK, Kim ES. Unlocking marine treasures: Isolation and mining strategies of natural products from sponge-associated bacteria. Natural Product Reports, 2025, 42(7), 1195-1225. DOI: 10.1039/d5np00013k
[9]Ahmed I, Asgher M, Sher F, Hussain SM, Nazish N, Joshi N, et al. Exploring marine as a rich source of bioactive peptides: Challenges and opportunities from marine pharmacology. Marine Drugs, 2022, 20(3), 208. DOI: 10.3390/md20030208
[10]Mohanty I, Tapadar S, Moore SG, Biggs JS, Freeman CJ, Gaul DA, et al. Presence of bromotyrosine alkaloids in marine sponges is independent of metabolomic and microbiome architectures. Msystems, 2021, 6(2), e01387-20. DOI: 10.1128/mSystems.01387-20
[11]Li Q, Ye Z, Wang G, Chen Y, Deng J, Wang D, et al. Natural products as novel therapeutic agents for triple-negative breast cancer: Current evidence, mechanisms, challenges, and opportunities. Molecules, 2025, 30(6), 1201. DOI: 10.3390/molecules30061201
[12]Qin R, You FM, Zhao Q, Xie X, Peng C, Zhan G, et al. Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: From molecular mechanisms to potential therapeutic targets. Journal of Hematology & Oncology, 2022, 15(1), 133. DOI: 10.1186/s13045-022-01350-z
[13]De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Franceschini R, Tancredi R, et al. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds. Frontiers in Pharmacology, 2022, 13, 909566. DOI: 10.3389/fphar.2022.909566
[14]Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies. Frontiers in Oncology, 2024, 14, 1405491. DOI: 10.3389/fonc.2024.1405491
[15]Brun Usan M, Nunes-da-Fonseca R, Kavanagh KD, Moustakas-Verho JE, Zimm R. Editorial: Eco-evo-devo: An emergent integrative discipline of biology. Frontiers in Cell and Developmental Biology, 2025, 13, 1681036. DOI: 10.3389/fcell.2025.1681036
[16]Hafez Ghoran S, Taktaz F, Ayatollahi SA, Kijjoa A. Anthraquinones and their analogues from marine-derived fungi: Chemistry and biological activities. Marine Drugs, 2022, 20(8), 474. DOI: 10.3390/md20080474
[17]Jamal A, Arif A, Shahid MN, Kiran S. Plant secondary metabolites inhibit cancer by targeting epidermal growth factor receptor (EGFR): An updated review on their regulation and mechanisms of action. Asian Pacific Journal of Cancer Biology, 2025, 10(1), 191-206. DOI: 10.31557/APJCB.2025.10.1.191.
[18]Banday AH, ul Azha N, Farooq R, Sheikh SA, Ganie MA, Parray MN, et al. Exploring the potential of marine natural products in drug development: A comprehensive review. Phytochemistry Letters, 2024, 59, 124-135. DOI: 10.1016/j.phytol.2024.01.001
[19]Ferreira Montenegro P, Pham GN, Abdoul-Latif FM, Taffin-de-Givenchy E, Mehiri M. Marine bromotyrosine derivatives in spotlight: Bringing discoveries and biological significance. Marine Drugs, 2024, 22(3), 132. DOI: 10.3390/md22030132
[20]Yadav S K, Dahal S, Khadka R, Guragain B, Pokharel P, Oli P, et al. First Principles study of electronic, vibrational, elastic, and thermodynamic properties of Sc‐X (X=P, S, Se) compounds. Engineering Reports, 2025, 7(1), e13115. DOI: 10.1002/eng2.13115
[21]Hosseini H, Al-Jabri HM, Moheimani NR, Siddiqui SA, Saadaoui I. Marine microbial bioprospecting: Exploitation of marine biodiversity towards biotechnological applications-a review. Journal of Basic Microbiology, 2022, 62(9), 1030-1043. DOI: 10.1002/jobm.202100504
[22]Khademi F. Therapeutic bioactives and their progressive extraction, fractionation, and analytical techniques: A comprehensive review. Choice, 2024, 18, 38-44.
[23]de Souza ALC, do Rego Pires A, Moraes CAF, de Matos CHC, dos Santos KIP, Campos e Silva R, et al. Chromatographic methods for separation and identification of bioactive compounds. Drug discovery and design using natural products. Cham: Springer Nature Switzerland, 2023, 153-176. DOI: 10.1007/978-3-031-35205-8_6
[24]Shakoor R, Hussain N, Younas S, Bilal M. Novel strategies for extraction, purification, processing, and stability improvement of bioactive molecules. Journal of Basic Microbiology, 2023, 63(3-4), 276-291. DOI: 10.1002/jobm.202200401
[25]Khairul Anuar NFS, Abdul Wahab R, Huyop F, Normi YM, Susanti E, Jumbri K. Rational redesigning the Acinetobacter haemolyticus lipase KV1 for improved polyethylene terephthalate degradation via molecular docking and dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2026, 44(8), 4014-4044. DOI: 10.1080/07391102.2025.2570786
[26]Asma ST, Acaroz U, Imre K, Morar A, Shah SRA, Hussain SZ, et al. Natural products/bioactive compounds as a source of anticancer drugs. Cancers, 2022, 14(24), 6203. DOI: 10.3390/cancers14246203
[27]Zheng C, Li M, Ding J. Challenges and opportunities of nanomedicines in clinical translation. BIO Integration, 2021, 2(2), 57. DOI: 10.15212/bioi-2021-0016
[28]Martínez H, Santos M, Pedraza L, Testera AM. Advanced technologies for large scale supply of marine drugs. Marine Drugs, 2025, 23(2), 69. DOI: 10.3390/md23020069
[29]Tan LT. Impact of marine chemical ecology research on the discovery and development of new pharmaceuticals. Marine Drugs, 2023, 21(3), 174. DOI: 10.3390/md21030174
[30]Potapskyi E, Kustrzyńska K, Łażewski D, Skupin-Mrugalska P, Lesyk R, Wierzchowski M. Introducing bromine to the molecular structure as a strategy for drug design. Journal of Medical Science, 2024, 93(3), e1128-e1128. DOI: 10.20883/medical.e1128
[31]Nudelman A. Dimeric drugs. Current Medicinal Chemistry, 2022. 29(16), 2751-2845. DOI: 10.2174/0929867328666210810124159
[32]Pecio Ł, Pecio S, Mroczek T, Oleszek W. Spiro-Flavonoids in nature: A critical review of structural diversity and bioactivity. Molecules, 2023, 28(14), 5420. DOI: 10.3390/molecules28145420
[33]Johnson BM, Shu YZ, Zhuo X, Meanwell NA. Metabolic and pharmaceutical aspects of fluorinated compounds. Journal of Medicinal Chemistry, 2020, 63(12), 6315-6386. DOI: 10.1021/acs.jmedchem.9b01877
[34]Cotas J, Leandro A, Monteiro P, Pacheco D, Figueirinha A, Gonçalves AMM, et al. Seaweed phenolics: From extraction to applications. Marine Drugs, 2020, 18(8), 384. DOI: 10.3390/md18080384
[35]Bouyahya A, Mechchate H, Oumeslakht L, Zeouk I, Aboulaghras S, Balahbib A, et al. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: Mechanistic pathways and pharmacodynamic actions. Biomolecules, 2022, 12(3), 367. DOI: 10.3390/biom12030367
[36]Siam MSH. A review on synthesis and SARs of select natural alkaloids as anticancer agents. Brac University, 2024.
[37]Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. International Journal of Molecular Sciences, 2022, 23(4), 2288. DOI: 10.3390/ijms23042288
[38]Medina MA, Oza G, Sharma A, Arriaga LG, Hernández Hernández JM, Rotello VM, et al. Triple-negative breast cancer: A review of conventional and advanced therapeutic strategies. International Journal of Environmental Research and Public Health, 2020, 17(6), 2078. DOI: 10.3390/ijerph17062078
[39]Nortje E. Evaluation of a strategy based on multi-drug targeting of cancer proteins in breast cancer cell lines. University of Pretoria (South Africa), 2020.
[40]Witt BL, Tollefsbol TO. Molecular, cellular, and technical aspects of breast cancer cell lines as a foundational tool in cancer research. Life, 2023, 13(12), 2311. DOI: 10.3390/life13122311
[41]Vasilev B, Atanasova M. A (comprehensive) review of the application of quantitative structure__activity relationship (QSAR) in the prediction of new compounds with anti-breast cancer activity. Applied Sciences, 2025, 15(3), 1206. DOI: 10.3390/app15031206
[42]Selvaraj C, Santhosh R, Alothaim AS, Vijayakumar R, Desai D, Safi SZ, et al. Advances in cancer therapy: Unveil the immunomodulatory protein involved in signaling pathways as molecular targets. Chemical Papers, 2025, 79(6), 3493-3511. DOI: 10.1007/s11696-025-04007-6
[43]Batool S, Asim L, Qureshi FR, Masood A, Mushtaq M, Saleem RSZ. Molecular targets of plant-based alkaloids and polyphenolics in liver and breast cancer- an insight into anticancer drug development. Anti-Cancer Agents in Medicinal Chemistry, 2025, 25(5), 295-312. DOI: 10.2174/0118715206302216240628072554
[44]D de Araujo E, B Wright T, Saqib B, W Keillor J, T Gunning P. An introduction to medicinal chemistry & molecular recognition. 2024.
[45]Oluwabusola ET, Katermeran NP, Poh WH, Goh TMB, Tan LT, Diyaolu O, et al. Inhibition of the quorum sensing system, elastase production and biofilm formation in pseudomonas aeruginosa by psammaplin A and bisaprasin. Molecules, 2022, 27(5), 1721. DOI: 10.3390/molecules27051721
[46]Okafor S, Njoku A, Okeke C. In silico investigation of novel compounds of marine origin as potential migrastatics: Molecular docking and molecular dynamics studies. 2023.
[47]Prebble DW, Er S, Xu M, Hlushchuk I, Domanskyi A, Airavaara M, et al. α-synuclein aggregation inhibitory activity of the bromotyrosine derivatives aerothionin and aerophobin-2 from the subtropical marine sponge Aplysinella sp. Results in Chemistry, 2022, 4, 100472. DOI: 10.1016/j.rechem.2022.100472
[48]Kalinski JJ, Polyzois A, Waterworth SC, Siwe Noundou X, Dorrington RA. Current perspectives on pyrroloiminoquinones: Distribution, biosynthesis and drug discovery potential. Molecules, 2022, 27(24), 8724. DOI: 10.3390/molecules27248724
[49]Payne M, Fossatti L, Chamberland S. On the halogenation of tyrosine N‐oxime methyl ester. European Journal of Organic Chemistry, 2025, 28(4), e202401153. DOI: 10.1002/ejoc.202401153
[50]Lyakhova I, Piatkova M, Khotimchenko Y, Zhidkov M, Kantemirov A, Khotimchenko R, et al. 3-Bromofascaplysin is a prospective chemical compound for developing new chemotherapy agents in glioblastoma treatment. International Review of Neurobiology, 2020, 151, 325-343. DOI: 10.1016/bs.irn.2020.03.011
[51]Sinane M, Grunberger C, Gentile L, Moriou C, Chaker V, Coutrot P, et al. Potential of marine sponge metabolites against prions: Bromotyrosine derivatives, a family of interest. Marine Drugs, 2024, 22(10), 456. DOI: 10.3390/md22100456
[52]Daoud NE, Borah P, Deb PK, Venugopala KN, Hourani W, Alzweiri M, et al. ADMET profiling in drug discovery and development: Perspectives of in silico, in vitro and integrated approaches. Current Drug Metabolism, 2021, 22(7), 503-522. DOI: 10.2174/1389200222666210705122913
[53]Seliem IA. Synthesis, cytotoxic activity, molecular docking, molecular dynamics simulations, and ADMET studies of novel spiropyrazoline oxindoles based on domino Knoevenagel-Michael cyclization as potent non-toxic anticancer agents targeting β-tubulin and EGFR, with anti-MRSA activity. RSC advances, 2025, 15(26), 20495-20512. DOI: 10.1039/d5ra01257k
[54]Szulc A, Woźniak M. Targeting pivotal hallmarks of cancer for enhanced therapeutic strategies in triple-negative breast cancer treatment-in vitro, in vivo and clinical trials literature review. Cancers, 2024, 16(8), 1483. DOI: 10.3390/cancers16081483
[55]Murniasih T, Putra MY, Bayu A, Wibowo JT. A review on diversity of anticancer compounds derived from Indonesian marine sponges. IOP Conference Series: Materials Science and Engineering. IOP Publishing, 2021, 1192(1), 012012. DOI: 10.1088/1757-899X/1192/1/012012
[56]Dewi C, Fristiohady A, Amalia R, Khairul Ikram NK, Ibrahim S, Muchtaridi M. Signaling pathways and natural compounds in triple-negative breast cancer cell line. Molecules, 2022, 27(12), 3661. DOI: 10.3390/molecules27123661
[57]Nelson VK, Nuli MV, Mastanaiah J, Saleem TSM, Birudala G, Jamous YF, et al. Reactive oxygen species mediated apoptotic death of colon cancer cells: Therapeutic potential of plant derived alkaloids. Frontiers in Endocrinology, 2023, 14, 1201198. DOI: 10.3389/fendo.2023.1201198
[58]Serrano Muñoz AJ. Preclinical evaluation of the antitumoral potential of antipsychotic phenothiazines in brain metastatic breast cancer cells. 2021.
[59]Matulja D, Wittine K, Malatesti N, Laclef S, Turks M, Markovic MK, et al. Marine natural products with high anticancer activities. Current Medicinal Chemistry, 2020, 27(8), 1243-1307. DOI: 10.2174/0929867327666200113154115
[60]Rahman N, Khan H, Zia A, Khan A, Fakhri S, Aschner M, et al. Bcl-2 modulation in p53 signaling pathway by flavonoids: A potential strategy towards the treatment of cancer. International Journal of Molecular Sciences, 2021, 22(21), 11315. DOI: 10.3390/ijms222111315
[61]Malabadi RB, Sadiya MR, Kolkar KP, Mammadova SS, Chalannavar RK, Baijnath H, et al. Triple negative breast cancer (TNBC): Signalling pathways-Role of plant-based inhibitors. Journal of Biology and Pharmacy, 2024, 10(2), 028-071. DOI: 10.53022/oarjbp.2024.10.2.0013
[62]He G, Feng Y, Chen T, Zhang Y, Liang L, Yan J, et al. Chrysosplenetin B suppresses the growth of human prostate cancer cells by inducing G1 cell cycle arrest. Bioimpacts, 2025, 15, 30688. DOI: 10.34172/bi.30688
[63]Sala S, Micke SK, Flematti GR. Marine natural products from flora and fauna of the Western Australian coast: Taxonomy, isolation and biological activity. Molecules, 2023, 28(3), 1452. DOI: 10.3390/molecules28031452
[64]Kashyap A, Sarma A, Das BK, Goswami AK. Rational design of natural products for drug discovery. Computational Methods for Rational Drug Design, 2025, 285-309. DOI: 10.1002/9781394249190.ch13
[65]Shrivastav G, Dubey A, Kumari M, Shukla, T. Advances in pharmacognosy for modern drug discovery and development. Journal of Biosciences and Public Health, 2025, 1(3), 45-63. DOI: 10.5455/JBPH.2025.14
[66]Zhang L, Liu B, Zhu T, Tian X, Chen N, Wang Y. Advances in the study of halogenated natural products. Current Topics in Medicinal Chemistry, 2025, 25(10), 1217-1250. DOI: 10.2174/0115680266344796241211214414
[67]Matés JM, Sánchez-Jiménez FM. Role of reactive oxygen species in apoptosis: Implications for cancer therapy. The International Journal of Biochemistry & Cell Biology, 2000, 32(2), 157-170. DOI: 10.1016/s1357-2725(99)00088-6
[68]Tewari D, Priya A, Bishayee A, Bishayee A. Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin. Clinical and Translational Medicine, 2022, 12(4), e795. DOI: 10.1002/ctm2.795
[69]El-Demerdash A, Hassan A, Abd El-Aziz TM, Stockand JD, Arafa RK. Marine brominated tyrosine alkaloids as promising inhibitors of SARS-CoV-2. Molecules, 2021, 26(20), 6171. DOI: 10.3390/molecules26206171
[70]Vakili SA, George A, Ayatollahi SA, Martorell M, Ostrander EA, Salehi B, et al. Phenolic compounds, saponins and alkaloids on cancer progression: Emphasis on p53 expression and telomere length. Cellular and Molecular Biology, 2020, 66(4), 110-119. DOI: 10.14715/cmb/2020.66.4.15
[71]Esposito G, Ponticelli M, Milella L, Lela L, Teta R, Pawlik JR, et al. Bioassay-guided procedure coupled with hr-esims dereplication for isolation of antiproliferative bromo-tyramine derivative from aplysina cauliformis. Marine Drugs, 2025, 23(5), 187. DOI: 10.3390/md23050187
[72]Dorna D, Grabowska A, Paluszczak J. Natural products modulating epigenetic mechanisms by affecting histone methylation/demethylation: Targeting cancer cells. British Journal of Pharmacology, 2025, 182(10), 2137-2158. DOI: 10.1111/bph.16237
[73]Yu YS, Kim IS, Baek SH. Decoding the dual role of autophagy in cancer through transcriptional and epigenetic regulation. FEBS letters, 2025, 599(16), 2237-2249. DOI: 10.1002/1873-3468.70060
[74]Das C, Adhikari S, Bhattacharya A, Chakraborty S, Mondal P, Yadav SS, et al. Epigenetic-metabolic interplay in the DNA damage response and therapeutic resistance of breast cancer. Cancer Research, 2023, 83(5), 657-666. DOI: 10.1158/0008-5472.CAN-22-3015
[75]Tilaoui M, Ait Mouse H, Zyad A. Update and new insights on future cancer drug candidates from plant-based alkaloids. Frontiers in Pharmacology, 2021, 12, 719694. DOI: 10.3389/fphar.2021.719694
[76]Zhou J, Wang L, Peng C, Peng F. Co-targeting tumor angiogenesis and immunosuppressive tumor microenvironment: A perspective in ethnopharmacology. Frontiers in Pharmacology, 2022, 13, 886198. DOI: 10.3389/fphar.2022.886198
[77]Radosinska D, Radosinska J. The link between matrix metalloproteinases and Alzheimer's disease pathophysiology. Molecular Neurobiology, 2025, 62(1), 885-899. DOI: 10.1007/s12035-024-04315-0
[78]Mustafa M, Abbas K, Alam M, Ahmad W, Moinuddin, Usmani N, et al. Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC). Molecular and Cellular Biochemistry, 2024, 479(4), 895-913. DOI: 10.1007/s11010-023-04772-6
[79]Pache MM, Thorat AS, Mule RR, Pradhan KH, Watane RG, Jagtap MN. Recent advances in the use of alkaloids as therapeutic agents: A pharmacognostic perspective. World Journal of Pharmaceutical Research, 2025, 14(2), 538-552. DOI: 10.20959/wjpr20252-35316
[80]Batista VF, Pinto DCGA, Silva AMS. Recent in vivo advances of spirocyclic scaffolds for drug discovery. Expert Opinion on Drug Discovery, 2022, 17(6), 603-618. DOI: 10.1080/17460441.2022.2055544
[81]Pandey S, Mondal S, Kajal K, Kurmi BD, Verma SK, Patel P. Current progress in the targeted therapy of breast cancer: Structure-activity correlation and docking studies (2015-2021). Archiv der Pharmazie__Chemistry in Life Sciences, 2023, 356(8), e2200602. DOI: 10.1002/ardp.202200602
[82]Püsküllüoğlu M, Michalak I. The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer. Frontiers in Pharmacology, 2024, 15, 1349242. DOI: 10.3389/fphar.2024.1349242
[83]Janic A, Abad E, Amelio I. Decoding p53 tumor suppression: A crosstalk between genomic stability and epigenetic control? Cell Death & Differentiation, 2025, 32(1), 1-8. DOI: 10.1038/s41418-024-01259-9
[84]Tian M, Ma J, Li Z, Ye C, Cui X, Wang G, et al. Senescent cells promote viral infection-associated inflammation and tissue damage through a robust NF-κB pathway. Cell Communication and Signaling, 2025, 23(1), 464. DOI: 10.1186/s12964-025-02466-8
[85]Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. International Journal of Molecular Sciences, 2020, 22(1), 173. DOI: 10.3390/ijms22010173
[86]Ramesha KP, Chandra Mohana N, Chandra Nayaka S, Satish S. Epigenetic modifiers revamp secondary metabolite production in endophytic Nigrospora sphaerica. Frontiers in Microbiology, 2021, 12, 730355. DOI: 10.3389/fmicb.2021.730355
[87]Yang D, Peng D, Li H, Jia D, Zhou Y, Hu B, et al. The type I ribosome-inactivating protein α-MMC induced significant apoptosis of lung cancer A549 and 95-D cells by activating the caspase cascade through TNF signaling pathway. Frontiers in Pharmacology, 2025, 16, 1529151. DOI: 10.3389/fphar.2025.1529151
[88]Sies H, Belousov VV, Chandel NS, Davies MJ, Jones DP, Mann GE, et al. Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology. Nature Reviews Molecular Cell Biology, 2022, 23(7), 499-515. DOI: 10.1038/s41580-022-00456-z
[89]Adams W, Understanding the role of cell cycle regulation in cancer. American Journal of Biological Sciences, 2025, 6(3), 5-9. DOI: 10.71465/ajbs2334
[90]Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. Biomaterials and Biosystems, 2024, 13, 100090. DOI: 10.1016/j.bbiosy.2024.100090
[91]Chitoran E, Rotaru V, Stefan DC, Gullo G, Simion L. Blocking tumoral angiogenesis VEGF/VEGFR pathway: Bevacizumab-20 years of therapeutic success and controversy. Cancers, 2025, 17(7), 1126. DOI: 10.3390/cancers17071126
[92]Shahid S, Shah SH, Rahman A, Advani RS, Shiblee SA, Adeel-Ur-Rehman, et al. How specific signaling pathways like Wnt, Notch, and Hedgehog regulate cancer stem cells, and potential therapies targeting these pathways. Indus Journal of Bioscience Research, 2025, 3(4), 733-742. DOI: 10.70749/ijbr.v3i4.1178
[93]Palit P, Mandal SC. Climate change, geographical location, and other allied triggering factors modulate the standardization and characterization of traditional medicinal plants: A challenge and prospect for phyto-drug development. Evidence based validation of traditional medicines: A comprehensive approach. Singapore: Springer Singapore, 2021, 359-369. DOI: 10.1007/978-981-15-8127-4_18
[94]Shahiwala A, Khopade AJ, Patravale VB. Commercial scale production of nanomedicines. CRC Press, 2025.
[95]Salib MN, Hendra R, Molinski TF. Bioactive bromotyrosine alkaloids from the bahamian marine sponge Aiolochroia crassa. Dimerization and oxidative motifs. The Journal of Organic Chemistry, 2022, 87(19), 12831-12843. DOI: 10.1021/acs.joc.2c01415
[96]Gould O, Drabińska N, Ratcliffe N, de Lacy Costello B. Hyphenated mass spectrometry versus real-time mass spectrometry techniques for the detection of volatile compounds from the human body. Molecules, 2021, 26(23), 7185. DOI: 10.3390/molecules26237185
[97]Kanagaraja A, Sakthivelu M, Raman P. Methods for isolation and characterization of plant alkaloids. Natural Products: Phytochemistry, Botany, Metabolism of Alkaloids, Phenolics and Terpenes. Berlin, Heidelberg: Springer Berlin Heidelberg, 2025, 1-29.
[98]Song JG, Ye WC, Wang Y. Advanced crystallography for structure determination of natural products. Natural Product Reports, 2025, 42(3), 429-442. DOI: 10.1039/d4np00071d
[99]Roostee SJ. Immune response in triple-negative breast cancer-machine learning-based insights from histology and-omics. Lund University, 2025.
[100]Ibrahim HA, El-Sheekh MM. Marine ecosystems: A unique source of valuable bioactive compounds. Bentham Science Publishers, 2023.
[101]Balogun SM, Agboola AR, Raji RO, Popoola DA. Therapeutic potential of non-plant-derived natural products in modern medicine: A systematic review of mechanisms, applications, and innovations. AROC in Natural Products Research, 2025, 5 (1), 11-22. DOI: 10.53858/arocnpr05011122
[102]Ganguly P, Saha P, Chatterjee S, Pati PP. Natural marine species bioactive compounds and their ethnopharmacological approach from ecological biodiversity: Sustainable therapeutic properties. Pharmacognosy Research, 2025, 17(3), 697-706. DOI: 10.5530/pres.20252162
[103]Morgan I. targeting triple-negative breast cancers: Discovery of novel lead compounds and their biological characterziation. Martin-Luther-Universität Halle-Wittenberg, 2024.
[104]Ramirez-Garcia JL, Lee-Harwood H, Ackerley D, Kelly M, Matoto SV, Hunt P, et al. Purpuramine R, a new bromotyrosine isolated from Pseudoceratina cf. verrucosa collected in the Kingdom of Tonga. Marine Drugs, 2025, 23(5), 186. DOI: 10.3390/md23050186
[105]Bhat Y, Thrishna MR, Banerjee S. Molecular targets and therapeutic strategies for triple-negative breast cancer. Molecular Biology Reports, 2023, 50(12), 10535-10577. DOI: 10.1007/s11033-023-08868-6
[106]Vagena IA, Malapani C, Gatou MA, Lagopati N, Pavlatou EA. Enhancement of EPR effect for passive tumor targeting: Current status and future perspectives. Applied Sciences, 2025, 15(6), 3189. DOI: 10.3390/app15063189
[107]Shi M, Li Z, Shen G, Wang T, Li J, Wang M, et al. Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis. Cancer Pathogenesis and Therapy, 2023, 2(2), 81-90. DOI: 10.1016/j.cpt.2023.06.002
[108]Stanley L. Drug metabolism, in Pharmacognosy. Elsevier, 2024, 597-624.
[109]Ruiz A, DiCristina S. Absorption to excretion: The aging body’s take on drugs__A review of pharmacokinetic changes and their impact on medication management. Current Pharmacology Reports, 2025, 11(1), 42. DOI: 10.1007/s40495-025-00425-y
[110]Haas M. Investigation of the hepatotoxic potency of selected genotoxic pyrrolizidine alkaloids and the significance of the DNA damage response. Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau, 2025.
[111]Kan LL, Chan BC, Leung PC, Wong CK. Natural-product-derived adjunctive treatments to conventional therapy and their immunoregulatory activities in triple-negative breast cancer. Molecules, 2023, 28(15), 5804. DOI: 10.3390/molecules28155804
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jeewanjot Singh, Subhi Sharma, Prabhjot Singh (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
